Clinical trial
The Effect of Medical Treatment on Muscle Dysfunction and the Prognostic Role of Muscle Dysfunction at Critical Decision Points in Patients With Hematological Diseases Referred to Myeloablative Hematopoietic Stem Cell Transplant (HSCT), to Myeloablative HSCT With a "Reduced Toxicity Conditioning" Regime With Fludarabine and Treosulfane (FluTreo), or to Non-myeloablative HSCT. - A Prospective Observational Study.
NCT04167683 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Medical Treatment on Muscle Dysfunction and the Prognostic Role of Muscle Dysfunction at Critical Decision Points in Patients With Hematological Diseases Referred to Myeloablative Hematopoietic Stem Cell Transplant (HSCT), to Myeloablative HSCT With a "Reduced Toxicity Conditioning" Regime With Fludarabine and Treosulfane (FluTreo), or to Non-myeloablative HSCT. - A Prospective Observational Study.
- Lead sponsor
- Rigshospitalet, Denmark
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- October 1, 2023
- Completion date
- November 1, 2026
- Enrollment
- 144 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hematologic diseases, myelodysplastic syndromes, non hodgkin lymphoma, stem cell transplant complications